Ustekinumab Injection for Plaque Psoriasis: Uses, Administration, Side Effects and Pharmacology

Overview:

A drug called Ustekinumab is used to treat and control some inflammatory diseases, such as inflammatory bowel disease (inflammation of the intestines), psoriasis (raised and scaly patches on the skin), and psoriatic arthritis (inflammatory conditions that affect joints and skin). On September 25, 2009, the FDA (Food and Drug Administration) initially authorized Ustekinumab for the treatment of moderate to severe plaque psoriasis in adults. Additionally, ulcerative colitis (inflammation in the colon and the rectum) and Crohn's disease (inflammation in the digestive tract) are treated with it. This article goes over Ustekinumab's uses, mechanisms of action, and contraindications as a useful treatment for inflammatory conditions. In the management of plaque psoriasis, this article will highlight the mechanism of action, adverse event profile, and other important factors relevant to members of the interprofessional team and patients.

Drug Group:

Ustekinumab is a specific anti-interleukin (IL) drug that operates mainly in the interleukin pathway and is classified under the biologics medicine class. Ligands are derived from live organisms and are intended to work against some of the components of the immune system of the body.

Available Doses and Dosage Forms:

• Subcutaneous Injection: 45 mg per 0.5 mL (milligrams per milliliter) or 90 mg per mL concentration of the solution for injection in a prefilled, single-dose syringe.

• Intravenous Infusion: Administer 130 mg per mL of a single dose of a vial containing five mg per mL of potassium in 26 mL of solution.

For Patients:

What is Ustekinumab?

Ustekinumab is an immunobiologic drug involved in the management of many autoimmune diseases including plaque psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis. It comes as a Ustekinumab injection that works on certain proteins in the immune system to reduce the production of proteins called interleukin-12 (IL-12) and interleukin-23 (IL-23).

Inflammation Thus, Ustekinumab dosage depends on a particular disease, the weight of the patient, and its reaction to the therapy. It is usually administered in the first dose while the patient needs subsequent maintenance doses at a certain frequency. Ustekinumab is best used for managing and preventing several forms of chronic autoimmune diseases and in improving the patient’s quality of life. It is kindly suggested that you always consult a doctor concerning the frequency of intake and the way to take the medicine.

What Is Ustekinumab Used for?

Ustekinumab is especially useful in managing autoimmune diseases, especially psoriatic arthritis. It is also used for moderate and severe Crohn’s disease and ulcerative colitis when other treatments have failed. A little bit about what Ustekinumab does to the patient’s immune system: Ustekinumab helps to diminish inflammation and ease signs and symptoms by interfering with particular proteins in the body. Patients on Ustekinumab should also know some of the drug interactions as it has been said that it may interact with other immunosuppressants, increasing the likelihood of infections. Due to interaction with other medications, vaccines, and treatments, patients are advised first to consult their doctors before using Ustekinumab.

How Does Ustekinumab Work?

Ustekinumab is a monoclonal antibody that selectively binds to IL-12 and IL-23 cytokines, which are critical for the inflammatory process associated with psoriasis. Plaque psoriasis, which is a chronic autoimmune skin disease, is characterized by the rapid division of skin cells and the development of thick, red, scaly skin patches. These plaques are painful and may often be associated with irritation. Although it can occur in any part of the body, it largely presents itself in the elbows, knees, scalp, and lower back regions. The severity of the disease known as plaque psoriasis differs; it may also cause psoriatic arthritis and other issues.

Ustekinumab reduces cytokines that cause inflammation and overproduction of skin cells and therefore reduces the severity of symptoms of plaque psoriasis. This approach promotes better skin and contributes to immune system balance restoration.

What Is the Dosage of Ustekinumab?

It is observed that the patient’s weight and age determine the dose of Ustekinumab.

Adults: 45 mg subcutaneous injection given at the onset and after four weeks.

• In the 0th and 4th weeks, patients with body weight greater than 100 kg (kilograms) should be administered 90 mg of the drug subcutaneously.

• The maintenance dose administered subcutaneously is 45 mg every 12 weeks of treatment.

• In the case of patients with a baseline BMI (body mass index) greater than 35 kilograms per meter square, 90 mg subcutaneously every 12 weeks is recommended.

Pediatrics (12 Years of Age and Up): According to body weight, a healthcare professional should decide the dose of Ustekinumab.

The patient must stay super consistent with the recommended dosage and frequency.

How Effective Is Ustekinumab?

Randomized controlled trials also indicate that Ustekinumab is an excellent intervention for moderate to severe plaque psoriasis. Important details about its efficacy are as follows:

• Response Rates: Treatment outcomes also indicate that a large number of patients recall a significant reduction in the extent of their psoriasis, with a few patients attaining virtually no lesions or almost clear skin. It has been found in clinical trials of the long-term use of therapy that after 12 weeks, 70 to 80 percent of sufferers have at least 75 percent average improvement in the Psoriasis Area and Severity Index (PASI).

• Long-Term Efficacy: The long-term studies carried out have revealed that Ustekinumab still has a positive effect, and more than one patient reported benefits.

• Quality of Life: Learners sometimes present a better attitude towards life because of a less severe condition and a clear complexion.

What are the things to inform the doctor about before taking Ustekinumab?

Tell the doctor about all of the medical problems before starting Ustekinumab, particularly if having:

• Neoplasms (cancer), life-threatening infectious diseases.

• Previous adverse reactions to the ingredients in Ustekinumab.

• Latex sensitivity (latex is used in the syringe needle cap).

• Live vaccines administered within the past two weeks or scheduled for the future (it is advised that anyone using Ustekinumab should not take live vaccines in the future).

• Those involving new development or change in skin areas that are not lesions or involve non-prosoriatic skin that becomes involved in the disease.

• If a person had ever been treated with phototherapy for psoriasis or allergy injections.

• Planning to get pregnant (consult the physician regarding the risks).

• Breastfeeding: It has, however, been determined that breast milk containing Ustekinumab may pass into the nursing infant.

• Make sure to inform them about any medication you are taking, over-the-counter medications, medical prescriptions, vitamins, and supplements.

How Is Ustekinumab Administered?

Ustekinumab is administered by subcutaneous injection. The following are included in the administration process:

• Preparation: It is mandatory to wipe the injection site with an alcohol swab. The outside arm, thigh, and belly are usual sites.

• Injection: The doses of Ustekinumab are normally given in two shots at week 0 and week 4 when the injection is 90 mg or a single shot when the dose is 45 mg for initial doses. Thereafter, maintenance doses are administered at 12-week intervals away from the infection site.

• Patient Education: The basic guidelines regarding injection technology are that patients should be instructed about how to administer injections themselves, and the proper ways of handling the medicine.

They should sustain proper instructions given by the doctor about taking the drugs, such as when to visit the doctor for follow-up and evaluate their therapy.

What Are the Side Effects of Ustekinumab?

Side effects of Ustekinumab include:

• Headache.

• Congested, stuffy nose, runny nose, or tiredness due to sneezing.

• Pain or swelling at the spot where the substance has been injected.

• Nausea.

• Vomiting.

• Joint pain.

Some of the undesirable effects can be fatal. Contact your physician right away if you encounter any of the following symptoms,

• Seizures.

• Disorientation.

• Vision changes.

• Itch, rashes, and hives.

• Tongue, eyelids, face, or throat that becomes swollen.

• Problems with the chest.

• The throat becomes rigid while breathing.

• Potential risk of developing cancers.

Dietary Considerations:

No specific restrictions on dietary habits are listed. Maintaining a balanced diet will support and improve overall well-being.

Missed Dose:

If a dosage is missed, it should be taken as soon as possible. If the next dose is due, then you should skip the dose and continue with the normal dosages. Do not take two doses at once. Seek advice from the physician. In either case, it is wiser to always consult the health care provider when you realize any doses are missing.

Overdose:

Clinical trials have been administered with intravenous single administration of up to six mg per kg without dose-limiting side effects. If a patient did overdose, then administer the correct symptomatic treatment and observe any signs of adverse effects. If looking for more tips on treating overdoses, it may be useful to consult with a physician toxicologist or with the poison helpline.

Storage:

• Prefilled syringes and Ustekinumab vials must be stored at a temperature between the range of two degrees Celsius (35.6 degrees Fahrenheit) and eight degrees Celsius (46.4 degrees Fahrenheit).

• Ustekinumab vials should also be stored in an upright position.

• Store Ustekinumab in its carton, away from light, until you are ready to use it.

• Do not freeze or shake Ustekinumab.

• In cases of individual Ustekinumab prefilled syringes, it is also possible to keep each syringe, as in the original carton, at room temperature for up to 30 days, up to 30 degrees Celsius (86 degrees Fahrenheit) while the light is shielded from the container.

• On the box, write the date when the prefilled syringe was first taken out of the refrigerator at the place where it is allowed.

• The syringe is not to be restored to the refrigerator once it has been left at room temperature. In the case where the syringe was not used for 30 days, it should be kept at room temperature and disposed of.

• When it comes to the expiring date of the prefilled syringe or carton, the Ustekinumab should not be used thereafter.

For Doctors:

Indication:

1. Adults

• Moderate to severe plaque psoriasis (PsO).

• Phototherapy or systemic therapy.

• Active psoriatic arthritis (PSA).

• Moderately to severely active Crohn’s Disease (CD).

• Moderately to severely active ulcerative colitis.

2. Pediatric Patients Six Years and Older:

Patients with moderate to severe form of plaque psoriasis can be treated with

phototherapy or systemic therapy. A less-included but significant subtype is active psoriatic arthritis (PsA).

Dose:

• Initial Dose: 45 mg subcutaneously with dosing at baseline and week four. For patients weighing over 100 kg, deaths occurred in 7.3 percent of patients receiving placebo and in 3.1 percent of patients receiving Ustekinumab 90 mg subcutaneously at weeks 0 and 4.

• Maintenance Dose: 45 milligrams subcutaneously every 12 weeks. For patients weighing over 100 kg, 90mg subcutaneously every 12 weeks for multiple myeloma patients.

• Pediatric Patients (Six years and Older): It is taken depending on the weight of the patient and this should be prescribed by a physician.

Dosing Considerations:

• Administration: The preferred route for the administration of Ustekinumab is the subcutaneous one. Self-administration, therefore, requires adequate training.

• Monitoring: Since there are side effects tied to the treatment as well as observing the effectiveness of the treatment, follow-up appointments are required.

• Modifications: Due to side effects or patient tolerance level variations in response to too much stress, modifications to dosage can be required.

• Risk of Infection: Infections should be suspected in the early treatment phase, especially in the response of the patient.

• Vaccinations: Discuss with your physician whether or not you have ever taken any immunizations, and in more cases, you should avoid live vaccines when opting for therapy.

What Are the Pharmacological Aspects of Ustekinumab?

Pharmacodynamics: Ustekinumab is a monoclonal antibody that targets interleukin-12 (IL-12) and interleukin-23 (IL-23), both of which are connected with immunological and inflammation processes. It decreases the above-mentioned cytokines that have certain inflammatory effects and lessens the lesions and symptoms in diseases like psoriasis and psoriatic arthritis.

Mechanism: Ustekinumab only targets the p40 subunit that both IL-12 and IL-23 have, preventing its binding with receptors on immune cells. Therefore, this activity reduces the inflammatory reactions associated with autoimmune diseases by inhibiting the downstream signal transduction pathways that stimulate T-helper cell activation and proliferation.

Pharmacokinetics

• Absorption: Ustekinumab is self-administered subcutaneously after the injection of the solution and has the following pharmacokinetic profile: T max is seven to 14 days.

• Distribution: Clearance into the extracellular space is suggested by the Vd (volume of distribution), which is approximately six L (liters) (1.58503 gallons).

• Metabolism: Like other monoclonal antibodies, Ustekinumab is primarily cleared as metabolites by proteolytic breakdown.

• Elimination: As a loading dose, the drug has a half-life of approximately 15 to 50 days, provided that dosing occurs every 12 weeks.
• Excretion: Again, there is minimum renal and hepatic clearance, while the reticuloendothelial system has the major responsibility of removing it.

The pharmacological factors affecting the effectiveness of Ustekinumab and the recommended dose schedule for the treatment of autoimmune diseases are described in this section.

Toxicity:

• Risk of Infection: As with other biologics, Ustekinumab has a potential immunosuppressive effect and, therefore, increases the risk of infection, especially tuberculosis and other atypical mycobacterial infections.

• Allergy Responses: Some people might feel allergic reactions, including anaphylaxis, but they are rare.

• Malignancy: While the potential adverse effects on late outcomes are being defined, some malignancies may be associated with the use of this technique.

• Reactions at the Injection Site: Most of the side effects are mainly manifested in redness, swelling, or itching at the point of injection.

Clinical Studies:

• Clinical trials show that Ustekinumab significantly reduces symptoms of psoriatic arthritis and plaque psoriasis. In general many patients after a course of treatment in 12 weeks received PASI 75 or Psoriasis Area and Severity Index being 75 percent.

• Relative to conventional systemic medicines, the safety profile of osseous medicines depicted in clinical studies is that while most side effects are ordinarily intolerable, ‘serious’ side effects are relatively rare.

• Current studies carried on over several years of therapy indicate improvement in safety and efficiency and possible side effects are also being in succession.

What Are the Contraindications of Ustekinumab?

• Hypersensitivity: Ustekinumab is contraindicated in patients with a documented history of sensitivity to Ustekinumab or any of the ingredients that are in the product.

• Active Infections: People with certain diseases, including tuberculosis-related cases, should not take it.

• Live Vaccines: In main before, during, and after the therapy patients are advised not to use any live vaccines.

• Pregnancy: Taking into consideration the possible negative effects and advantages of Ustekinumab, one must consider the case of using this medication in pregnant women. You should discuss the matter with your healthcare professional if you are pregnant or thinking about getting pregnant.

Therefore, those remarks should be made about the continuation of the safety and effectiveness of treating autoimmune diseases by using Ustekinumab.

Warnings and Precautions:

1. Infections: There have been severe infections reported. Ustekinumab should be initiated only clinically if an infection is significant or present at the point of initiating the therapy.

2. Theoretical Risk for Specific Infections: It is noteworthy that patients with genetic deficiencies in IL12 or IL-23 chains are prone to develop severe infections by mycobacteria, salmonella, and, contrariwise, severe adverse reactions to BCG vaccines. Take a look at these infections’ diagnostic tests with the aspects of the clinical situation in mind.

• Tuberculosis (TB): Patients should first be checked for TB (tuberculosis) when the Ustekinumab treatment is to be initiated. It is recommended to begin treatment for latent TB before using Ustekinumab units for their consumption.

• Cancers: Some people taking Ustekinumab have had skin cancer. It has remained unestablished whether Ustekinumab is safe in individuals with a history of malignancy or those with one known.

• Hypersensitivity Reactions: This warning applies to anaphylactic reactions or that may manifest as any other clinically significant hypersensitivity reaction.

• Posterior Reversible Encephalopathy Syndrome (PRES): Discontinue using Ustekinumab and start treating the condition right from the time when it has been diagnosed.

• Vaccinations: The patients who take Ustekinumab therapy should avoid getting live vaccines.

• Noninfectious Pneumonia: In the post-marketing tables when using Ustekinumab it has been associated with interstitial pneumonia, eosinophilic pneumonia, and cryptogenic organizing pneumonia. If the diagnosis is verified, then Ustekinumab should be terminated, and the right therapeutic approach must be introduced.

What Are the Drug Interactions of Ustekinumab?

• Immunosuppressive Medications: One should be very careful if they are on several immunosuppressive drugs at the same time, as this may increase the chances of infections.

• Live Vaccinations: Live vaccinations should not be taken together with it.

• Other Biological Products: No information on safety and efficacy regarding the coadministration of Ustekinumab with other TNF (tumor necrosis factor)-or other immunosuppressive biologic agents is available at present.

• Cytochrome P450 Inducers or Inhibitors: It is safe to use Ustekinumab for patients with liver disease, but its metabolism is not significantly affected by the liver; thus, it should not be used with drugs that affect cytochrome P450 enzymes.

Specific Considerations:

• Pregnancy and Breastfeeding: Any woman who is pregnant or desiring to get pregnant should consult her healthcare provider about the benefits and risks associated with pregnancy during Ustekinumab therapy. If you intend to breastfeed after taking Ustekinumab, you should consult the doctor. This medicine may be present in breast milk.

• Use in Pediatrics: The manufacturer does not recommend the use of this product for children below the age of six years hence the effects of the product on young children are unknown. If taken in pediatric children who are six years and above, it should be taken constantly.

• Senior Clients: Other than age, it is improper to prescribe specific alterations in dose because of age; just watch for side effects and increased chances of getting an infection.